Fig. 4: Expression of plasma-miRNA panel for FSGS diagnosis in the validation phase. | Cell Death & Disease

Fig. 4: Expression of plasma-miRNA panel for FSGS diagnosis in the validation phase.

From: Plasma microRNA panel is a novel biomarker for focal segmental glomerulosclerosis and associated with podocyte apoptosis

Fig. 4

a Expression of miR-17, miR-451, miR-106a, and miR-19b in plasma of FSGS (n = 50) and healthy controls (n = 68). b ROC analysis of individual miRNAs for the diagnosis of FSGS. c ROC analysis of four-miRNA panel for the diagnosis of FSGS in validation set. d ROC curves of the four-miRNA panel generated by analyzing all 221 samples from training, validation, and blinded-test sets. e ROC curve of serum creatinine for the diagnosis of FSGS in the training, validation and blinded-test phases. *P < 0.05, ***P < 0.001

Back to article page